The concept of engineering robust protein scaffolds for novel binding functions emerged 20
years ago, one decade after the advent of recombinant antibody technology. Early examples …

Imaging of expression of therapeutic targets may enable stratification of patients for targeted
treatments. The use of small radiolabeled probes based on the heavy-chain variable region …

The targeted delivery of radionuclides to tumours holds great promise for diagnosis and
treatment of malignant neoplasms. The development of scaffold proteins has significantly …

Targeting of human epidermal growth factor type 2 (HER2) using monoclonal antibodies,
antibody-drug conjugates and tyrosine kinase inhibitors extends survival of patients with …

The use of radiolabelled antibodies was proposed in 1970s for staging of malignant
tumours. Intensive research established chemistry for radiolabelling of proteins and …

Designed ankyrin repeat proteins (DARPins) are small engineered scaffold proteins that can
be selected for binding to desirable molecular targets. High affinity and small size of …

High expression of human epidermal growth factor receptor 2 (HER2) in breast and
gastroesophageal carcinomas is a predictive biomarker for treatment using HER2‐targeted …

В настоящем обзоре обсуждается относительно новый класс направленных адресных
молекул, активно исследующийся в отношении радионуклидной диагностики и лечения …

Initially emerging as a highly innovative concept in the late 1990s, the concept of creating
novel binding reagents based on stable protein scaffolds from outside the immunoglobulin …

ADAPTs are small engineered non-immunoglobulin scaffold proteins, which have
demonstrated very promising features as vectors for radionuclide tumour targeting …